Targeted delivery of CXCR4-siRNA by scFv for HER2+ breast cancer therapy

Biomaterials

Volumn 59, Issue , 2015, Pages 77-87

  Jiang, Kuo ^a   Li, Jia ^b   Yin, Jipeng ^b   Ma, Qiong ^a   Yan, Bo ^c   Zhang, Xiang ^c   Wang, Lei ^c   Wang, Lifeng ^c   Liu, Tao ^a   Zhang, Yinglong ^a   Fan, Qingyu ^a   Yang, Angang ^c   Qiu, Xiuchun ^a   Ma, Baoan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer therapy; CXCR4; Single chain antibody fragment; SiRNA delivery

Indexed keywords

AMINO ACIDS; ANTIBODIES; BIOSYNTHESIS; CELL CULTURE; CELL DEATH; DISEASES; ENZYME ACTIVITY; GENE EXPRESSION; ONCOLOGY; PATHOLOGY; RNA;

BREAST CANCER; BREAST CANCER XENOGRAFTS; CLINICAL APPLICATION; CXCR4; INNATE IMMUNE RESPONSE; SHORT INTERFERING RNA; SINGLE-CHAIN ANTIBODIES; SIRNA DELIVERY;

GENE THERAPY;

CHEMOKINE RECEPTOR CXCR4; DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY NONAMER PEPTIDE FUSION PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CXCR4 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER GENE THERAPY; CANCER INHIBITION; CELL PROLIFERATION; EXPRESSION VECTOR; GENE EXPRESSION; IN VITRO STUDY; INNATE IMMUNITY; METASTASIS; MOUSE; NONHUMAN; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PURIFICATION; ANIMAL; BREAST NEOPLASMS; DRUG SCREENING; GENETICS; HUMAN; PATHOLOGY; PROTO ONCOGENE;

MUS;

ANIMALS; BREAST NEOPLASMS; GENES, ERBB-2; HUMANS; MICE; RECEPTORS, CXCR4; RNA, SMALL INTERFERING; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930160223     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.04.030     Document Type: Article

References (35)

1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer J Int du Cancer 2015, 136:E359-E386.
2. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (New York, NY) 1989, 244:707-712.
3. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol Off J Am Soc Clin Oncol 2005, 23:4265-4274.
4. Esteva F.J., Valero V., Booser D., Guerra L.T., Murray J.L., Pusztai L., et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol 2002, 20:1800-1808.
5. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540-550.
6. Juarez J.G., Thien M., Dela Pena A., Baraz R., Bradstock K.F., Bendall L.J. CXCR4 mediates the homing of B cell progenitor acute lymphoblastic leukaemia cells to the bone marrow via activation of p38MAPK. Br J Haematol 2009, 145:491-499.
7. Zheng H., Dai T., Zhou B., Zhu J., Huang H., Wang M., et al. SDF-1alpha/CXCR4 decreases endothelial progenitor cells apoptosis under serum deprivation by PI3K/Akt/eNOS pathway. Atherosclerosis 2008, 201:36-42.
8. Fernandis A.Z., Prasad A., Band H., Klosel R., Ganju R.K. Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene 2004, 23:157-167.
9. Salvucci O., Yao L., Villalba S., Sajewicz A., Pittaluga S., Tosato G. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 2002, 99:2703-2711.
10. Bachelder R.E., Wendt M.A., Mercurio A.M. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res 2002, 62:7203-7206.
11. Li Y.M., Pan Y., Wei Y., Cheng X., Zhou B.P., Tan M., et al. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 2004, 6:459-469.
12. Holm N.T., Byrnes K., Li B.D., Turnage R.H., Abreo F., Mathis J.M., et al. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. J Surg Res 2007, 141:53-59.
13. Mukherjee D., Zhao J. The role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res 2013, 3:46-57.
14. Lapteva N., Yang A.G., Sanders D.E., Strube R.W., Chen S.Y. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo. Cancer Gene Ther 2005, 12:84-89.
15. Liang Z., Yoon Y., Votaw J., Goodman M.M., Williams L., Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005, 65:967-971.
16. Kumar P., Wu H., McBride J.L., Jung K.E., Kim M.H., Davidson B.L., et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007, 448:39-43.
17. Wen W.H., Liu J.Y., Qin W.J., Zhao J., Wang T., Jia L.T., et al. Targeted inhibition of HBV gene expression by single-chain antibody mediated small interfering RNA delivery. Hepatology (Baltimore, Md) 2007, 46:84-94.
18. Yao Y.D., Sun T.M., Huang S.Y., Dou S., Lin L., Chen J.N., et al. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis. Sci Transl Med 2012, 4:130-148.
19. Jia L.T., Zhang L.H., Yu C.J., Zhao J., Xu Y.M., Gui J.H., et al. Specific tumoricidal activity of a secreted proapoptotic protein consisting of HER2 antibody and constitutively active caspase-3. Cancer Res 2003, 63:3257-3262.
20. Zhao J., Zhang L.H., Jia L.T., Zhang L., Xu Y.M., Wang Z., et al. Secreted antibody/granzyme B fusion protein stimulates selective killing of HER2-overexpressing tumor cells. J Biol Chem 2004, 279:21343-21348.
21. Qiu X.C., Xu Y.M., Wang F., Fan Q.Y., Wang L.F., Ma B.A., et al. Single-chain antibody/activated BID chimeric protein effectively suppresses HER2-positive tumor growth. Mol Cancer Ther 2008, 7:1890-1899.
22. Ren J.L., Meng Y.L., Hu B., Jia L.T., Zhang R., Xu Y.M., et al. The effect of direct translocation across endosomes on the cytotoxicity of the recombinant protein e23sFv-Fdt-casp6 to HER2 positive gastric cancer cells. Biomaterials 2011, 32:7641-7650.
23. Judge A., MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 2008, 19:111-124.
24. Davis M.E., Zuckerman J.E., Choi C.H., Seligson D., Tolcher A., Alabi C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010, 464:1067-1070.
25. Lee S.J., Son S., Yhee J.Y., Choi K., Kwon I.C., Kim S.H., et al. Structural modification of siRNA for efficient gene silencing. Biotechnol Adv 2013, 31:491-503.
26. Jackson A.L., Linsley P.S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat Rev Drug Discov 2010, 9:57-67.
27. Kanasty R., Dorkin J.R., Vegas A., Anderson D. Delivery materials for siRNA therapeutics. Nat Mater 2013, 12:967-977.
28. Nguyen J., Szoka F.C. Nucleic acid delivery: the missing pieces of the puzzle?. Acc Chem Res 2012, 45:1153-1162.
29. Ashihara E., Kawata E., Maekawa T. Future prospect of RNA interference for cancer therapies. Curr Drug Targets 2010, 11:345-360.
30. Oh Y.K., Park T.G. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 2009, 61:850-862.
31. Boisguerin P., Deshayes S., Gait M.J., O'Donovan L., Godfrey C., Betts C.A., et al. Delivery of therapeutic oligonucleotides with cell penetrating peptides. Adv Drug Deliv Rev 2015 Mar 4, PMID 25747758, pii: S0169-409X(15)00019-8, [Epub ahead of print]. 10.1016/j.addr.2015.02.008.
32. Zeller S., Choi C.S., Uchil P.D., Ban H.S., Siefert A., Fahmy T.M., et al. Attachment of cell-binding ligands to arginine-rich cell-penetrating peptides enables cytosolic translocation of complexed siRNA. Chem Biol 2015, 22:50-62.
33. Whitehead K.A., Dahlman J.E., Langer R.S., Anderson D.G. Silencing or stimulation? siRNA delivery and the immune system. Annu Rev Chem Biomol Eng 2011, 2:77-96.
34. Robbins M., Judge A., MacLachlan I. siRNA and innate immunity. Oligonucleotides 2009, 19:89-102.
35. Rozema D.B., Lewis D.L., Wakefield D.H., Wong S.C., Klein J.J., Roesch P.L., et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci U S A 2007, 104:12982-12987.